Mazumdar Claire 4
4 · Bicara Therapeutics Inc. · Filed Dec 18, 2025
Insider Transaction Report
Form 4
Mazumdar Claire
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Common Stock
2025-12-16$5.45/sh+29,500$160,884→ 339,392 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-12-16−29,500→ 565,512 totalExercise: $5.45Exp: 2033-12-14→ Common Stock (29,500 underlying)
Footnotes (1)
- [F1]The shares underlying this option vest in sixteen equal quarterly installments following December 14, 2023, subject to the Reporting Person's continued service on each such vesting date.